Home Contact Sitemap

eRAM

encyclopedia of Rare Disease Annotation for Precision Medicine




Disease juvenile myoclonic epilepsy
Symptom C0234535|clonic seizures
Sentences 11
PubMedID- 25950944 Chr: chromosome, start/end: genomic start and end position of the deleted segment, hg19; gge, genetic generalised epilepsy; gge syndromes: cae: childhood absence epilepsy, jae: juvenile absence epilepsy, jme: juvenile myoclonic epilepsy, egma: epilepsy with generalised tonic-clonic seizures alone predominantly on awakening, egtcs: epilepsy with generalised tonic-clonic seizures alone, gsw: generalised spike and wave discharges on the electroencephalogram, number/: age-at-onset of afebrile generalised seizures.
PubMedID- 25667841 Levetiracetam (s)-alpha-ethyl-2-oxo-1-pyrrolidine acetamide (lev) is a second generation anticonvulsant approved by the european medicines agency (ema) and/or the u.s. food and drug administration (fda) for the following: 1) monotherapy treatment of partial seizures, with or without secondary generalization (ema); 2) adjunctive treatment of partial seizures, with or without secondary generalization (fda/ema); 3) adjunctive treatment of myoclonic seizures associated with juvenile myoclonic epilepsy (fda/ema); and 4) adjunctive treatment of primary generalized tonic–clonic seizures associated with idiopathic generalized epilepsy (fda/ema) .
PubMedID- 25874548 Gge, genetic generalized epilepsies; cae, childhood absence epilepsy; jae, juvenile absence epilepsy; jme, juvenile myoclonic epilepsy; egtcs, epilepsy with generalized tonic-clonic seizures.
PubMedID- 23986742 The oral form has food and drug administration (fda) indications for adjunctive therapy in the treatment of partial onset epilepsy ages 1 month or more, myoclonic seizures associated with juvenile myoclonic epilepsy starting with the age of 12 and primary generalized tonic-clonic seizures in people 6 years and older.
PubMedID- 24883310 In 2011, liu investigated the wm differences between normal controls and two subsets of ige, juvenile myoclonic epilepsy and ige with generalized tonic-clonic seizures only.
PubMedID- 21395360 Worldwide, levetiracetam is most commonly approved as adjunctive treatment of partial onset seizures with or without secondary generalization; other approved indications include monotherapy treatment of partial onset seizures with or without secondary generalization, and adjunctive treatment of myoclonic seizures associated with juvenile myoclonic epilepsy and primary generalized tonic-clonic (gtc) seizures associated with idiopathic generalized epilepsy.
PubMedID- 24027645 Levetiracetam is an established second-generation antiepileptic drug that is approved as a treatment of partial seizures; other indications include adjunctive treatment of myoclonic seizures associated with juvenile myoclonic epilepsy and primary generalized tonic-clonic seizures associated with generalized epilepsy.
PubMedID- 21936590 Worldwide, levetiracetam is most commonly approved as adjunctive treatment of partial-onset seizures with or without secondary generalization; other approved indications include monotherapy treatment of partial-onset seizures with or without secondary generalization, and adjunctive treatment of myoclonic seizures associated with juvenile myoclonic epilepsy and primary generalized tonic-clonic (gtc) seizures associated with idiopathic generalized epilepsy.
PubMedID- 20087210 Latencies were significantly shorter in juvenile absence epilepsy than in juvenile myoclonic epilepsy, epilepsy with generalized tonic-clonic seizures only, and ige not further classified (p = 0.001).
PubMedID- 25767482 Based on the age of onset and seizure type, ige can be divided into four syndromes according to the still valid classification of the international league against epilepsy: childhood absence epilepsy, occurring after the neonatal period; juvenile absence epilepsy; juvenile myoclonic epilepsy; and ige with tonic–clonic seizures alone4.
PubMedID- 24009559 At present, lev is a worldwide commonly used second generation aed, approved as adjunctive and monotherapy treatment of partial-onset seizures with or without secondary generalization, and adjunctive treatment of myoclonic seizures associated with juvenile myoclonic epilepsy and primary generalized tonic-clonic seizures associated with idiopathic generalized epilepsy (lyseng-williamson, 2011).

Page: 1